How semaglutide reduces cardiovascular risk — and what the evidence actually shows

The myth worth correcting first: it's not just about the weight coming off

A common assumption is that GLP-1 medicines like semaglutide lower cardiovascular risk simply because patients lose weight, and lighter bodies put less strain on the heart. That is part of the picture, but it is not the whole story, and the trial data make that clear.

The SELECT trial enrolled 17,604 adults with a BMI of 28 or above and pre-existing cardiovascular disease, but without type 2 diabetes. Participants who received 2.4mg semaglutide weekly (the same dose used in Wegovy for weight management) experienced around a 20% reduction in the combined risk of non-fatal heart attack, non-fatal stroke, and cardiovascular death compared with placebo, over roughly four years. Crucially, the cardiovascular benefit was consistent across subgroups, including those who lost relatively little weight. That finding points to mechanisms that run alongside, not merely through, weight reduction.

Researchers have identified several plausible direct effects: GLP-1 receptors are present in cardiac and vascular tissue; semaglutide appears to reduce arterial inflammation and improve endothelial function; it also lowers blood pressure modestly and reduces certain inflammatory markers. The NEJM's account of the STEP 1 trial and subsequent SELECT analyses both support the view that cardiometabolic improvements exceed what weight loss alone would predict. None of this means the drug replaces statins, antihypertensives, or aspirin, it sits alongside established cardiovascular care.

What the UK licence and prescribing criteria actually say

The MHRA has granted Wegovy a distinct UK authorisation for reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity (BMI 30 or above) or overweight (BMI 27–29.9) with at least one weight-related condition. This is a separate indication from weight management, though the medicine and dose are the same.

In practice, how does Wegovy reduce cardiovascular risk within the NHS and private prescribing? A prescriber considers the specific licence criteria: confirmed cardiovascular disease (not simply elevated risk factors) plus the relevant BMI threshold. Not everyone who has had a heart attack automatically qualifies; the prescriber weighs your full cardiac and metabolic history. NHS England's guidance on weight-management injections outlines the wraparound clinical support expected alongside the medicine, and that same framework applies to the cardiovascular indication.

If you have read about this indication and are wondering whether it applies to your situation, that is precisely the conversation to have during a clinical consultation rather than trying to match criteria yourself. The nuances (which cardiac diagnoses count, how recent they need to be, what other medicines you are already taking) require a trained prescriber's eye. Our clinical team, led by our independent prescribers, works through this with every patient.

Side effects and cardiovascular considerations during treatment

If you are reading this because you have heart disease and are weighing whether to start semaglutide, it is natural to feel cautious. Concern about adding a new medicine to an already complicated regimen is reasonable, not anxious. The good news is that the safety profile in SELECT (where every participant had established cardiovascular disease) was broadly consistent with what is known from general obesity trials.

Common side effects remain gastrointestinal: nausea, loose stools, constipation, and indigestion are most frequent early in treatment or after dose increases, and most people find they settle within a few weeks. There is a detailed overview on the Wegovy side effects page. For people with heart conditions, dehydration from severe nausea or vomiting deserves particular attention because it can affect blood pressure and kidney function, staying hydrated matters, and prescribers often advise slowing titration if GI symptoms are difficult. Practical guidance on managing this is covered on reducing nausea on Wegovy, and if you want broader advice on keeping side effects to a minimum, our page on how to reduce semaglutide side effects covers helpful strategies across the full treatment journey.

Heart rate: semaglutide causes a small, generally clinically insignificant increase in resting heart rate (around 1–5 beats per minute in most studies). This is worth knowing about and worth mentioning to your cardiologist or GP if you are already being monitored for arrhythmia. It does not prevent use in most patients, but it should be disclosed.

The NHS semaglutide medicines page lists the full side-effect profile in accessible language and is worth bookmarking for reference throughout your treatment.

When to get medical help, and how to report concerns

Most side effects from semaglutide are manageable and resolve with time, but some symptoms need prompt medical attention. Seek urgent help for severe or persistent abdominal pain, particularly pain that radiates to your back, this can indicate acute pancreatitis, which the MHRA identified as a known but uncommon serious risk in its January 2026 Drug Safety Update for GLP-1 medicines. Do not wait it out.

Other reasons to contact a healthcare professional without delay: signs of a serious allergic reaction (swelling of the face or throat, difficulty breathing), significant chest pain or palpitations that feel different from your usual pattern, sudden changes in vision, or symptoms of severe dehydration such as dizziness and no urination for many hours. For people already living with cardiovascular disease, any new cardiac symptom should be taken seriously regardless of what medicine you are on.

If you experience a suspected side effect, you can report it directly to the MHRA via the Yellow Card scheme, a service for patients as well as professionals. Reports help regulators build a clearer picture of real-world safety and can lead to updated guidance.

If you are unsure whether a symptom is serious, that uncertainty is itself a reason to call 111 or your GP rather than searching online. You can also contact our team for aftercare support seven days a week. A fuller discussion of the risk profile sits on the semaglutide risks page, and if you want to read more about managing side effects day to day, the practical side-effects guide is a useful companion.

If after reading this you want to understand whether Wegovy is clinically appropriate for you, our prescribers discuss suitability and side effects in full as part of the consultation, speak to our prescribers to get started.